LAMP1 and COVID-19: Despite this, De Biasi et al. demonstrated opposite data highlighting augmented effector properties in CD8+ T cells from COVID-19 patients such as elevated IL-2 and IL-17A in vitro production as well as higher expression of the CD107a degranulation marker compared with healthy subjects [44].